Table 1.
Celiac disease-related relative risks for lymphoma and gastrointestinal carcinoma.
| Group | Total number | Celiac disease n (%) | No celiac disease n (%) | Adjusteda RR (95% CI) |
|---|---|---|---|---|
| Control group | ||||
| BCC/melanoma | 576,971 | 282 (0.05%) | 576,689 (99.95%) | 1.0 (reference) |
| Case group | ||||
| T-cell NHL | 4046 | 63 (1.6%) | 3983 (98.4%) | 35.8 (27.1–47.4)b |
| B-cell NHL | 25,183 | 17 (0.07%) | 25,166 (99.93%) | 1.4 (0.9–2.3) |
| Hodgkin lymphoma | 8076 | 3 (0.04%) | 8073 (99.96%) | 1.0 (0.3–3.3) |
| Adenocarcinoma esophagus | 18,322 | 12 (0.07%) | 18,310 (99.93%) | 1.5 (0.8–2.6) |
| Squamous cell carcinoma esophagus | 9776 | 16 (0.2%) | 9760 (99.8%) | 3.5 (2.1–5.8)b |
| Adenocarcinoma stomach | 32,281 | 12 (0.04%) | 32,269 (99.96%) | 0.8 (0.4–1.4) |
| Adenocarcinoma duodenum | 3237 | 16 (0.5%) | 3221 (99.5%) | 10.2 (6.2–17.0)b |
| Adenocarcinoma jejunum/ileum | 2129 | 15 (0.7%) | 2114 (99.3%) | 14.4 (8.5–24.2)b |
| Adenocarcinoma colorectal | 195,244 | 105 (0.05%) | 195,139 (99.95%) | 1.1 (0.9–1.4) |
| Squamous cell carcinoma anus | 3043 | 2 (0.07%) | 3041 (99.93%) | 1.4 (0.3–5.5) |
BCC: basal cell carcinoma; CI: confidence interval; n: number; NHL: non-Hodgkin lymphoma; RR: relative risk; SCC: squamous cell carcinoma.
a
Adjusted for gender and age at case or control diagnosis, based on unconditional logistic regression.
b
Statistically significant.